[Comment] CPX-351: an attractive option for the treatment of older patients with high-risk or secondary acute myeloid leukaemia

After 5 years of follow-up, the improved overall survival with CPX-351 versus 7+3 was maintained, which supports the previous evidence that CPX-351 can contribute to long-term remission and improved overall survival in patients aged 60–75 years with newly diagnosed high-risk or secondary acute myeloid leukaemia.

留言 (0)

沒有登入
gif